University of Pennsylvania 5th annual conference on statistical issues in Clinical Trials: Emerging statistical issues in biomarker validation (afternoon session)

Abstract

Get full access to this article

View all access options for this article.

References

http://www.lexjansen.com/pharmasug/2012/DG/PharmaSUG-2012-DG13.pdf (accessed 7 July 2103).

Barker

Sigman

Kelloff

. I-SPY-2: An adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009; 86: 97–100.

http://www.c-path.org/pdf/FDADraftDDTools.pdf (accessed 24 June 2013).

Federal Register/Vol. 77, No. 49/Tuesday, March 13, 2012/Notices.

Joffe

Greene

. Related causal frameworks for surrogate outcomes. Biometrics 2009; 65(2): 530–38.

Prentice

. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med 1989; 8: 431–40.

Kim

Herbst

Wistuba

. The BATTLE trial: Personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44–53.

Liu

Lin

Chow

. Inference on treatment effects for targeted clinical trials under enrichment design. Pharm Stat 2009; 8: 356–70.

Wang

Hung

HMJ

O’Neill

. Genomic classifier for patient enrichment: Misclassification and type I error issues in pharmacogenomics non-inferiority trial. Stat Biopharm Res 2011; 3: 310–19.

10.

Kosinski

Barnhart

. A global sensitivity analysis of performance of a medical diagnostic test when verification bias is present. Stat Med 2003; 22(17): 2711–21.